rFactor VIII deficit questioned

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A

rFVIIIFc (efraloctocog alfa, Eloctate®) is an extended half-life (EHL) factor VIII licensed for use in patients with hemophilia A for prophylaxis and treatment of bleeding and surgical episodes. Pharmacokinetic studies in adults have shown a mean 1.5-fold increase in half-life compared to full-length factor VIII. When compared to adults, the half-life is decreased by 8% in adolescents between 1...

Asbestos findings questioned.

The relationship between autocrine interferon (IFN) production and the expression of class I Major Histocompatibility Complex (MHC) membrane glycoproteins in vitro was investigated in a panel of murine transformed cells of nonhaemopoietic origin. The panel included 11 cell lines of H-2Kb haplotype derived from fibrosarcomas, carcinomas and melanoma, and from transformed fibroblasts. IFN activit...

Key Alzheimer's findings questioned.

When Stephen Strittmatter discovered an unexpected link between key proteins in two devastating brain maladies — Alzheimer’s disease and Creutzfeldt–Jakob disease (CJD) — researchers in the field agreed that he was on to something big. But a year on, conflicting results, including findings published in Nature this month, have clouded that rosy picture and highlight the challenge faced by resear...

Value of e-prescribing questioned.

© 2011 Canadian Medical Association or its licensors CMAJ, October 4, 2011, 183(14) 1575 Decades after Canada’s 33 700 pharmacists began buying computers in the expectation that provincial health systems would connect them with physicians through electronic prescription networks, such information sharing may be inching toward becoming a reality. Although skeptics say the primary rationale for s...

Canada's approach to biosimilars questioned.